Related Experiment Video
Updated: Jun 25, 2025
15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
9.6K
Update on recent advances in amyotrophic lateral sclerosis.
Nilo Riva1, Teuta Domi2, Laura Pozzi2
13Rd Neurology Unit and Motor Neuron Disease Centre, Fondazione IRCCS "Carlo Besta" Neurological Insitute, Milan, Italy. nilo.riva@istituto-besta.it.
Journal of Neurology
|May 27, 2024
Summary
Recent advances in understanding amyotrophic lateral sclerosis (ALS) molecular mechanisms are paving the way for gene therapy. New assistive technologies enhance personalized care for ALS patients, improving overall management.
Area of Science:
- Neuroscience
- Genetics
- Clinical Medicine
Background:
- Significant progress in understanding the molecular basis of amyotrophic lateral sclerosis (ALS).
- Emerging gene therapy strategies offer new treatment avenues.
- Advancements in assistive technologies enable personalized supportive and symptomatic care.
Purpose of the Study:
- To provide a comprehensive update on recent ALS research.
- To highlight the latest clinical trial results.
- To outline future directions in ALS patient management.
Main Methods:
- Review of recent scientific literature on ALS pathogenesis.
- Analysis of current clinical trial data.
- Synthesis of emerging trends in multidisciplinary ALS care.
Main Results:
- Enhanced understanding of ALS molecular mechanisms.
- Early-stage translation of research findings into clinical practice, including gene therapy.
- Improved personalized care through assistive technologies.
Conclusions:
- The integration of molecular insights and technological advancements is transforming ALS management.
- Future research should focus on refining gene therapies and optimizing multidisciplinary care strategies.
- Continued progress promises improved outcomes and quality of life for ALS patients.
Related Concept Videos
01:15Parkinson's Disease: Overview
528
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
528
01:26Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
01:26Cross-bridge Cycle
117.3K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.3K
01:22Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:22iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K